PODD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Insulet Corp (PODD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong revenue growth and maintains a leading position in its market, recent negative news regarding a product defect and bearish technical indicators suggest caution. Additionally, the lack of strong trading signals and mixed analyst sentiment further support a hold recommendation.
The technical indicators for PODD are bearish. The MACD histogram is negative and expanding downward, RSI is neutral but leaning towards oversold territory, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 217.554, with resistance at 231.306.
Insiders are buying, with a significant increase of 409.88% in insider buying over the last month.
The company reported strong Q4 revenue growth of 31.18% YoY, indicating robust business performance.
Analysts maintain a generally positive long-term outlook on the company's market position and growth potential.
Recent news of a design defect in the Omnipod 5 insulin pods has caused a 6.9% drop in share price and raised concerns about product reliability.
Technical indicators are bearish, with the stock trading near its support level.
Analysts have lowered price targets, citing competitive pressures and concerns about the insulin pump market.
The MACD and moving averages suggest a downward trend.
In Q4 2025, Insulet Corp reported revenue growth of 31.18% YoY to $783.8M. Net income increased slightly by 0.89% YoY to $101.6M, and EPS rose by 3.60% YoY to 1.44. Gross margin improved marginally to 72.54%. While revenue growth is strong, net income and EPS growth are relatively modest.
Analysts maintain a generally positive long-term outlook but have recently lowered price targets due to competitive pressures and concerns about the insulin pump market. Despite the recent negative news, several analysts reiterate Buy or Outperform ratings, with price targets ranging from $286 to $435.
